Poziotinib Shows Encouraging Activity Among Heavily Pretreated NSCLC Subgroup

Cancer News

Excerpt from OncLive:

“Poziotinib (NOV120101, HM781-36B) demonstrated high antitumor activity in patients with metastatic, heavily pretreated EGFR and HER2 exon 20 mutant non–small cell lung cancer (NSCLC), according to phase II study results presented at the 19th World Conference on Lung Cancer (WCLC) in Toronto, Canada.

To date, the agent specifically induced a best response rate of 55%, including a 43% confirmed objective response rate (ORR) among evaluable patients with EGFR exon 20 mutant NSCLC in the study, said John V. Heymach, MD, PhD, who presented data of the investigator-initiated study of poziotinib in EGFR and HER 2-exon 20 mutant NSCLC (NCT03066206).”

Go to full article published by OncLive on Sep 24, 2018.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Back to Cancer Insights